Akehurst R - Search Results

1

Cost-utility analysis of deferasirox compared to standard therapy with desferrioxamine for patients requiring iron chelation therapy in the United Kingdom.

Karnon J, Tolley K, Oyee J, Jewitt K, Ossa D, Akehurst R. Karnon J, et al. Among authors: akehurst r. Curr Med Res Opin. 2008 Jun;24(6):1609-21. doi: 10.1185/03007990802077442. Epub 2008 Apr 24. Curr Med Res Opin. 2008. PMID: 18439348

2

Modelling the long term cost effectiveness of clopidogrel for the secondary prevention of occlusive vascular events in the UK.

Karnon J, Brennan A, Pandor A, Fowkes G, Lee A, Gray D, Coshall C, Nicholls C, Akehurst R. Karnon J, et al. Among authors: akehurst r. Curr Med Res Opin. 2005 Jan;21(1):101-12. doi: 10.1185/030079904x18036. Curr Med Res Opin. 2005. PMID: 15881481

3

A critique and impact analysis of decision modeling assumptions.

Karnon J, Brennan A, Akehurst R. Karnon J, et al. Among authors: akehurst r. Med Decis Making. 2007 Jul-Aug;27(4):491-9. doi: 10.1177/0272989X07300606. Med Decis Making. 2007. PMID: 17761961

4

A cost-utility analysis of clopidogrel in patients with non-ST-segment-elevation acute coronary syndromes in the UK.

Karnon J, Bakhai A, Brennan A, Pandor A, Flather M, Warren E, Gray D, Akehurst R. Karnon J, et al. Among authors: akehurst r. Int J Cardiol. 2006 May 24;109(3):307-16. doi: 10.1016/j.ijcard.2005.06.026. Epub 2005 Jul 18. Int J Cardiol. 2006. PMID: 16026869

5

A cost-effectiveness analysis of celecoxib compared with diclofenac in the treatment of pain in osteoarthritis (OA) within the Swedish health system using an adaptation of the NICE OA model.

Brereton N, Pennington B, Ekelund M, Akehurst R. Brereton N, et al. Among authors: akehurst r. J Med Econ. 2014 Sep;17(9):677-84. doi: 10.3111/13696998.2014.933111. Epub 2014 Jun 30. J Med Econ. 2014. PMID: 24914585 Free article.

6

The cost-effectiveness of bosentan in the United Kingdom for patients with pulmonary arterial hypertension of WHO functional class III.

Stevenson MD, Macdonald FC, Langley J, Hunsche E, Akehurst R. Stevenson MD, et al. Among authors: akehurst r. Value Health. 2009 Nov-Dec;12(8):1100-5. doi: 10.1111/j.1524-4733.2009.00568.x. Epub 2009 Jun 25. Value Health. 2009. PMID: 19558373 Free article.

7

A cost-effectiveness analysis of MMX mesalazine compared with mesalazine in the treatment of mild-to-moderate ulcerative colitis from a UK perspective.

Brereton N, Bodger K, Kamm MA, Hodgkins P, Yan S, Akehurst R. Brereton N, et al. Among authors: akehurst r. J Med Econ. 2010 Mar;13(1):148-61. doi: 10.3111/13696990903562861. J Med Econ. 2010. PMID: 20141380 Free article.

8

Decision modeling to inform decision making: seeing the wood for the trees.

Karnon J, Brennan A, Akehurst R. Karnon J, et al. Among authors: akehurst r. Med Decis Making. 2010 May-Jun;30(3):E20-2. doi: 10.1177/0272989X10364245. Med Decis Making. 2010. PMID: 20489217 No abstract available.

9

The cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in patients with end-stage renal disease.

Brennan A, Akehurst R, Davis S, Sakai H, Abbott V. Brennan A, et al. Among authors: akehurst r. Value Health. 2007 Jan-Feb;10(1):32-41. doi: 10.1111/j.1524-4733.2006.00142.x. Value Health. 2007. PMID: 17261114 Free article.

10

Tramadol and the risk of fracture in an elderly female population: a cost utility assessment with comparison to transdermal buprenorphine.

Hirst A, Knight C, Hirst M, Dunlop W, Akehurst R. Hirst A, et al. Among authors: akehurst r. Eur J Health Econ. 2016 Mar;17(2):217-27. doi: 10.1007/s10198-015-0673-1. Epub 2015 Apr 11. Eur J Health Econ. 2016. PMID: 25861916 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

108 results

Search Page

Filters